108971 ⎘
Enzymes; Proenzymes; Compositions thereof ; Processes for preparing, activating, inhibiting, separating or purifying enzymes; Hydrolases (3) acting on peptide bonds (3.4); Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
GENE EDITING SYSTEMS AND METHODS FOR REDUCING IMMUNOGENICITY AND GRAFT VERSUS HOST RESPONSE
#2VARIANTS OF TEV PROTEASE AND USES THEREOF
#3Chimeric Antigen Receptor Polypeptides and Methods of Using Same
#4METHODS AND COMPOSITIONS
#5RECOMBINANT TYPE-I HUMANIZED COLLAGEN POLYPEPTIDE, AND PREPARATION METHOD THEREFOR AND USE THEREOF
#6UTILIZATION OF GENE TARGETING ANTIBODY FUSION PROTEINS TO PERFORM IN VIVO THERAPEUTIC GENE EDITING
#7METHOD FOR INDUCING A TOLEROGENIC IMMUNE RESPONSE
#8METHODS FOR CELL FREE PROTEIN SYNTHESIS AND POST TRANSLATIONAL MODIFICATION OF THE EXPRESSED PROTEINS
#9MUTANT PROTEASES AND USES THEREOF
#10SMALL MOLECULE-REGULATED GENE EXPRESSION SYSTEM
#11METHOD FOR EXPRESSING AND PURIFYING PROTEIN BY USING CSQ-TAG
#12METHODS AND PROTEINS FOR TARGETING MAIN PROTEASE OF CORONAVIRUS
#13PLATINUM/PEPTIDE/CUCURBITURIL COMPLESES: WELL-DEFINED ARCHITECTURES BUILT BY SUPRAMOLECULAR SELF-SORTING FOR THE TARGETING OF CYSTEINE PROTEASES
#14VLP ENTEROVIRAL VACCINES
#15NOVEL SCREENING PLATFORM TO IDENTIFY IMMUNE MODULATORY AGENTS
#16INHIBITION OF UNINTENDED MUTATIONS IN GENE EDITING
#17SYNTHETIC PROTEIN-LEVEL NEURAL NETWORK IN MAMMALIAN CELLS
#18METHODS FOR CONTROLLED ACTIVATION AND/OR EXPANSION OF GENETICALLY ENGINEERED CELLS USING POLYETHYLENE GLYCOL (PEG) RECEPTORS
#19ARTIFICIAL ALPHAVIRUS-DERIVED RNA REPLICON EXPRESSION SYSTEMS
#20C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS
#21DEVELOPMENT OF A NEW ENGINEERED TOBACCO ETCH VIRUS (TEV) PROTEASE ACTIVABLE IN THE CYTOSOL OR SECRETORY PATHWAY
#22SYNTHETIC PROTEIN CIRCUITS DETECTING SIGNAL TRANSDUCER ACTIVITY
#23INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF
#24RNA-based delivery systems with levels of control
#25Protease-controlled Secretion and Display of Intercellular Signals
#26EXPRESSION OF MODIFIED PROTEINS IN A PEROXISOME
#27INSULIN DEGLUDEC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
#28Inhibition of unintended mutations in gene editing
#29IMPROVED VARIANTS OF TEV PROTEASE FOR BIOTECHNOLOGICAL APPLICATIONS
#30SYNTHETIC ALPHA-SECRETASE AND USE THEREOF
#31NON-NATURALLY OCCURRING CAPSIDS FOR DELIVERY OF NUCLEIC ACIDS AND/OR PROTEINS
#32Artificial alphavirus-derived RNA replicon expression systems
#33ONCOLYTIC VIRUS AND APPLICATION THEREOF, AND DRUG FOR TREATING CANCER
#34PROTEOLYSIS-TARGETING VIRUS, LIVE VACCINE THEREOF, PREPARATION METHOD AND USE THEREOF
#35Fusion Constructs for Controlling Protein Function
#36Inhibition of unintended mutations in gene editing
#37REAGENTS AND METHODS FOR CONTROLLING PROTEIN FUNCTION AND INTERACTION
#38Methods and compositions
#39C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS
#40Programmable protein circuits in living cells
#41Inducible Cell Receptors for Cell-Based Therapeutics
#42Chimeric Antigen Receptor Polypeptides and Methods of Using Same
#43Compositions and Methods for Inducing Protein Function
#44Method for inducing a tolerogenic immune response
#45Flavivirus and alpha virus virus-like particles (VLPS)
#46METHODS AND SYSTEMS FOR PROTEIN REFOLDING
#47Biological synthesis of amino acid chains for preparation of peptides and proteins
#48NON-NATURALLY OCCURRING CAPSIDS FOR DELIVERY OF NUCLEIC ACIDS AND/OR PROTEINS
#49Recombinant RNA-Dependent RNA Polymerase of RNA Viruses
#50DEGRON FUSION CONSTRUCTS AND METHODS FOR CONTROLLING PROTEIN PRODUCTION
#51COMPOSITIONS AND METHOD FOR IDENTIFYING ENZYME AND TRANSPORT PROTEIN INHIBITORS
#52Rep protein for use in a diagnostic assay
#53RNA-based delivery systems with levels of control
#54Synthetic protein circuits detecting signal transducer activity
#55C-3 and C-17 modified triterpenoids as HIV-1 inhibitors
#56Transcriptional regulatory fusion polypeptide
#57Rewiring aberrant cancer signaling to a therapeutic effector response with a synthetic two-component system
#58Vaccines and pharmaceutical compositions against foot-and-mouth disease virus
#59DNA vaccines against foot-and-mouth disease virus
#60Method for producing foot-and-mouth disease virus (FMDV) viral proteins utilizing a modified FMDV 3C protease
#61METHODS AND SYSTEMS FOR PROTEIN REFOLDING
#62Processing engineered FMDV P1 polypeptide using an alternative TEV protease
#63SELECTIVE CELL-DEATH-INDUCING BINARY ENZYME SYSTEM
#64C-3 and C-17 modified triterpenoids as HIV-1 inhibitors
#65LIGHT-ACTIVATED, CALCIUM-GATED POLYPEPTIDE AND METHODS OF USE THEREOF
#66Processing of a modified foot-and-mouth disease virus P1 polypeptide by an alternative protease
#67Fluorescence amplification method for forward genetic discovery of factors in human mRNA degradation
#68Degron fusion constructs and methods for controlling protein production
#69Flavivirus and alphavirus virus-like particles (VLPS)
#70Modified foot-and-mouth disease virus 3C proteases, compositions and methods thereof
#71Method For Producing A Recombinant Protein Of Interest
#72CORRECTING CROSSTALK IN BIOLOGICAL SYSTEMS
#73Ligand-directed covalent modification of protein
#74HCV PROTEASE INHIBITORS AND USES THEREOF
#75Methods of intracellular conversion of single-chain proteins into their di-chain form
#76HCV protease inhibitors and uses thereof
#77Bimolecular protease-based biosensor
#78Fusion Protease
#79Protease-based biosensor
#80HCV protease inhibitors and uses thereof
#81Mutant Proteinase with Reduced Self-Cleavage Activity and Method of Purification
#82Method for preparing virus-like particle and recombinant baculovirus used therein
#83HCV PROTEASE INHIBITORS AND USES THEREOF
#84HCV vaccines and methods for using the same
#85METHODS AND SYSTEMS FOR PROTEIN REFOLDING
#86Method for inducing a tolerogenic immune response
#87Method for producing a recombinant protein of interest by using the Ntechnology
#88METHOD FOR PRODUCING A RECOMBINANT PROTEIN OF INTEREST
#89Methods of intracellular conversion of single-chain proteins into their di-chain form
#90Mutant proteinase with reduced self-cleavage activity and method of purification
#91METHOD FOR PREPARING VIRUS-LIKE PARTICLE AND RECOMBINANT BACULOVIRUS USED THEREIN
#92Activatable toxin complexes comprising a cleavable inhibitory peptide
#93Polynucleotides encoding engineered plant cysteine proteases and their uses
#94Amyloid-beta clearance
#95HCV protease inhibitors and uses thereof
#96Methods of intracellular conversion of single-chain proteins into their di-chain form
#97Mutant proteinase with reduced self-cleavage activity and method of purification
#98Processing enzymes fused to basic protein tags
#99HCV protease inhibitors and uses thereof
#100Compositions and methods for identifying enzyme and transport protein inhibitors
#101Production of recombinant proteins by autoproteolytic cleavage of a fusion protein
#102PROBE SET FOR IDENTIFICATION OF NUCLEOTIDE MUTATION, AND METHOD FOR IDENTIFICATION OF NUCLEOTIDE MUTATION
#103HCV vaccines and methods for using the same
#104Engineered potato virus A nuclear inclusion protein
#105Gene-transfer vector comprising helper-component protease gene of papaya ringspot virus for broad-spectrum virus resistance in crops and use thereof
#106LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN
#107Hepatitis C virus variants
#108"Method for screening compounds comprising the use of picornavirus protease 2A"
#109HCV NS3-NS4 Protease Resistance Mutants
#110Processing enzymes fused to basic protein tags
#111Protein expression system involving mutated severe respiratory syndrome-associated coronavirus 3C-like protease
#112ENZYME FOR THE PRODUCTION OF METHYLMALONYL-COENZYME A OR ETHYLMALONYL-COENZYME A AND USE THEREOF
#113CRYSTAL STRUCTURES OF HIV-1 PROTEASE INHIBITORS BOUND TO HIV-1 PROTEASE
#114Method for Identification and Development of Therapeutic Agents
#115HCV protease inhibitors and uses thereof
#116Glutamic acid-modified classical swine fever virus autoproteases N
#117HCV protease inhibitors and uses thereof
#118HCV protease inhibitors and uses thereof
#119RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS
#120Processing enzymes fused to basic protein tags
#121Affinity ligands
#122Hepatitis C virus non-structural NS3/4A fusion gene
#123Production of recombinant proteins by autoproteolytic cleavage of a fusion protein
#124Rapid method to determine inhibitor sensitivity of NS3/4A protease sequences cloned from clinical samples
#125HCV NS3-NS4 protease resistance mutants
#126Crystal structure of human coronavirus 229E main proteinase and uses for developing SARS inhibitors
#127Nucleic acids and new polypeptides associated with and/or overlapping with hepatitis C virus core gene products
#128Mutant proteinase with reduced self-cleavage activity and method of purification
#129Mutational profiles in HIV-1 protease correlated with phenotypic drug resistance
#130Hepatitis C virus variants
#131Purified active HCV NS2/3 protease
#132VIRAL PROTEASE
#133Purified active HCV NS2/3 protease
#134Resistant-repellent retroviral protease inhibitors
#135Resistance-repellent retroviral protease inhibitors
#136Method for identification and development of therapeutic agents
#1373D-structure model of SARS coronavirus 3CL protease and anti-SARS drugs
#138Assay system for screening protease inhibitors
#139Mutational profiles in HIV-1 protease correlated with phenotypic protease inhibitor resistance
#140Production of proteins
#141Full-length genomic RNA of papaya leaf-distortion mosaic virus
#142HCV NS3-NS4A protease resistance mutants
#143Nucleic acids and new polypeptides associated with and/or overlapping with hepatitis C virus core gene products
#144Inhibitor-resistant HCV NS3 protease